rs10759931 — TLR4 -2604G>A

TLR4 -2604G>A — When Your Immune Volume Control Is Turned Up

Toll-like receptor 4 is the innate immune system's primary alarm for Gram-negative bacteria and tissue damage. It scans for lipopolysaccharide (LPS)¹¹ lipopolysaccharide (LPS)
LPS is the outer membrane component of Gram-negative bacteria like E. coli and Salmonella; TLR4 binding LPS activates the NF-kB cascade, triggering production of inflammatory cytokines like TNF-α, IL-6, and IL-1β and signals from damaged cells. When TLR4 fires, it mobilizes the full inflammatory arsenal. This system must be calibrated precisely — too little and infections go undetected; too much and inflammation itself becomes the disease.

The rs10759931 variant (−2604G>A) sits in the TLR4 gene's promoter region — not in the protein itself, but in the switch that controls how much TLR4 protein is made. Carriers of the G allele produce more TLR4²² more TLR4
Quantified by RT-PCR in peripheral blood: GG+GA individuals show significantly higher TLR4 mRNA levels than AA homozygotes, with differential nuclear protein binding confirmed by electrophoretic mobility shift assay. That amplified expression translates into louder, more persistent inflammatory signaling — beneficial in acute infection, harmful as chronic background noise.

The Mechanism

rs10759931 lies approximately 2,604 base pairs upstream of the TLR4 transcription start site on chromosome 9q33.1 (plus strand). The G-to-A substitution alters the binding affinity of GATA-2, a transcription factor that governs TLR4 promoter activity. The G allele creates a stronger GATA-2 binding site, increasing basal and stimulus-induced TLR4 transcription.

This SNP functions as a cis-eQTL³³ cis-eQTL
A cis-expression quantitative trait locus: a genetic variant that regulates expression of a gene in close physical proximity, in contrast to trans-eQTLs that act on distant genes in whole blood — each additional G allele dose-dependently increases TLR4 mRNA. The effect cascades downstream: higher TLR4 surface density means more LPS binding, stronger MyD88/TRIF signaling, greater NF-kB activation, and elevated chronic production of pro-inflammatory cytokines. In healthy people this manifests as a more reactive baseline inflammatory state; in the presence of metabolic stress (hyperglycemia, oxidized LDL) or infection, the amplified response drives tissue damage.

Critically, the co-receptor CD14 is also upregulated in tandem with TLR4 in G-allele carriers, amplifying LPS delivery to TLR4 and further magnifying the inflammatory signal.

The Evidence

The foundational expression study by Ferronato et al.⁴⁴ Ferronato et al.
Gomez-Lira, Menegazzi, and colleagues, Journal of Human Genetics 2013 established that AA homozygotes express significantly less TLR4 mRNA in peripheral blood than GG or GA carriers, with differential transcription factor binding confirmed mechanistically. This expression effect has downstream consequences across several disease contexts.

Diabetic retinopathy: In 698 north Indian subjects with type 2 diabetes, Sohail et al.⁵⁵ Sohail et al. found that the combined risk genotype of rs10759931 was significantly associated with developing diabetic retinopathy (OR 1.50, p=0.05). Hyperglycemia activates TLR4 in retinal endothelial cells, and carriers of high-expression TLR4 promoter alleles sustain more inflammatory damage in the retinal microvasculature.

Cardiovascular disease: A Saudi Arabian cohort study found that the G allele of rs10759931 increased cardiovascular disease risk more than 1.5-fold in male patients⁶⁶ increased cardiovascular disease risk more than 1.5-fold in male patients, with GG frequency significantly elevated in patients over 60 years old versus controls. This is mechanistically coherent: oxidized LDL activates TLR4 in macrophages, and higher TLR4 expression amplifies the foam cell inflammatory cascade underlying atherosclerosis.

COPD and pulmonary inflammation: In a cohort of 110 COPD patients, Smit et al.⁷⁷ Smit et al. found that rs10759931 was associated with FEV1 decline and with significantly higher sputum inflammatory cell counts at baseline and over follow-up — reflecting the consequences of amplified pulmonary innate immune activity in response to chronic inhaled irritants.

COVID-19 cognitive outcomes: A 2023 Cell Reports study⁸⁸ Cell Reports study found that GG genotype at TLR4 -2604G>A was associated with worse cognitive outcomes in patients who had recovered from mild COVID-19. The SARS-CoV-2 spike protein directly activates TLR4, and blockade of TLR4 signaling prevented spike-induced synaptic loss and memory impairment in mouse models — making this promoter variant a plausible genetic modifier of post-COVID neuroinflammatory burden.

Cerebral cavernous malformations: In patients carrying KRIT1 mutations, rs10759931 G allele carriage was significantly associated with greater lesion number⁹⁹ significantly associated with greater lesion number, because elevated TLR4 expression amplifies the gut microbiome-driven TLR4-MEKK3-KLF2/4 signaling pathway that drives cavernous malformation growth.

Practical Actions

The G allele's main threat is sustained, low-grade amplification of the TLR4 inflammatory circuit. The actionable leverage points are: reducing the endogenous TLR4 ligands that drive chronic activation (oxidized LDL, advanced glycation end-products, gut-derived LPS), and monitoring for early signs of inflammatory complications in metabolically stressed tissues — particularly the retina and vasculature.

For GG carriers with diabetes, the diabetic retinopathy risk is specific and actionable: annual dilated fundus exams starting at diabetes diagnosis, optimizing glycemic control to reduce hyperglycemia-driven TLR4 activation, and attention to LDL oxidation as a direct TLR4 ligand.

Interactions

rs10759931 is distinct from the two coding TLR4 variants (rs4986790 Asp299Gly, rs4986791 Thr399Ile) that reduce TLR4 signaling by altering the LPS-binding domain. The promoter variant and the coding variants act through orthogonal mechanisms: rs10759931 changes how much TLR4 protein is made; the coding variants change how well that protein works. A carrier of rs4986790 (reduced LPS recognition) who is also GG at rs10759931 (high TLR4 expression) presents an interesting compound situation — quantitatively more receptor but qualitatively less sensitive per receptor. Both variants are already present in GeneOps; combined genotype interpretation warrants careful individualized assessment.

rs1927914, another TLR4 promoter SNP at position -2026, is also an eQTL that co-regulates TLR4 expression with rs10759931 in haplotype. These two promoter variants are often inherited together and their combined effect on TLR4 expression is additive. Carrying risk alleles at both further amplifies the expression increase.